Investigation of Refractory CMV (Cytomegalovirus) Infection or Disease, After Kidney Transplantation, Using UK (United Kingdom) National Registry of Rare Kidney Diseases (RaDaR)
This observational study intends to retrospectively gather information on cytomegalovirus (CMV) infection management in the United Kingdom (UK) over a period of 7 years (2017-2024). The main aims of this study are the following: * To estimate the overall prevalence and annual rate of adults with refractory CMV infection after a kidney transplant and describe how such CMV infections are treated * To describe how effective and well-tolerated the treatment was. * To describe the demographic and clinical characteristics of adult participants with CMV infection (refractory and non-refractory). In this study, already existing data will be reviewed and analysed from a UK database called the Registry of Rare Kidney Diseases (RaDaR) (NCT06065852). The study will only review data collected as part of routine clinical practice. The study will not impact the standard medical care and treatment of participants.
⁃ Refractory CMV group:
• Participants aged greater than or equal to (\>=) 18 years at index date
• Kidney transplant recipients on or subsequent to June 2016.
• CMV viraemia or disease identified as requiring treatment and which was refractory to previous CMV management (at least one course of therapy), with or without confirmed resistance.
• At least six months follow up time (except for participants who have died earlier).
⁃ Reference cohort of non-refractory CMV group:
• Participants aged \>=18 years.
• Kidney transplant recipients.
• Received initial CMV management (at least one course of therapy).
• At least six months follow up time (except for participants who have died earlier).